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ABSTRACT 
Sepsis is a serious life threatening medical emergency which, if not treated properly, oftentimes 
results in organ failure and death. Current sepsis treatment protocols are largely centered on the 
use of antibiotics and supportive care. Recent studies have suggested that antibiotics fail to be 
effective for sepsis treatment when administered during hypo-dynamic phase of sepsis that is 
usually characterized by the presence of a cytokine storm. As such, there is an urgent need to 
develop novel therapeutic drugs that target the inflammatory cytokines that are secreted as a 
result of increased reactive oxygen species. Cerium oxide nanoparticles (CeO2) have been shown 
to act as anti-inflammatory and anti-oxidant agent. More recently, they have been shown to 
attenuate polymicrobial insult-induced mortality in Sprague Dawley rats. Here, we investigated 
whether CeO2 nanoparticles can attenuate splenic damage in this animal model of sepsis. A 
single intravenous dose (0.5 mg/kg) of CeO2 nanoparticles attenuated the sepsis-induced loss in 
splenic cell structural integrity. These improvements in splenic structure were accompanied by a 
decrease in expression of late phase pro-inflammatory cytokine high mobility group box 1 
(HMGB1) along with reduced bacterial load in the blood and peritoneal fluid of septic animals. 
Taken together these findings suggest that CeO2 nanoparticles can be used to attenuate 
polymicrobial insult-induced splenic damage in Sprague dawley rats. 
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CHAPTER 1 
INTRODUCTION 
The term sepsis was first coined by Hippocrates who described sepsis as a process by 
which flesh rots and foul air develops near swamps (Marshall 2008). Scientists like Robert Koch, 
Louis Pasteur, and others postulated that microbial invasion was the prime cause of sepsis but 
they were not able to determine the type of pathogen responsible for the disease with any 
certainty at that time (Wilmut, Wongtawan et al. 2011). In non-coronary intensive care units, 
sepsis is the most common cause of mortality (Mayr, Yende et al. 2013). Sepsis is a serious 
medical condition whose incidence is increasing by approximately 13% each year (Messori, 
Fadda et al. 2014). This multifactorial disorder is characterized by widespread systemic 
inflammation that can lead to organ failure and death if not properly controlled. Sepsis is thought 
to occur as a result of infection by bacteria (gram positive and gram negative), fungi, and viruses 
that can rapidly progress in the aged and immunocompromised patients (Nasa, Juneja et al. 
2012). How sepsis causes organ failure is not well understood, but it is thought that the systemic 
inflammation caused by uncontrolled immune response results in release of several cytokines 
and inflammatory mediators that affect the vasculature. These inflammatory mediators disrupt 
the endothelial barrier and increase the vascular permeability which can lead to the development 
of hypotension and blood clots in the periphery. Each year approximately 700,000 cases of septic 
patients are admitted to the hospitals and nearly $16 billion is spent to treat the hospitalized 
patients (Garber, Gibney et al. 2002).  
Sepsis usually starts with the invasion of an infectious agent at the local or systemic level 
and gradually results in development of the systemic inflammatory response syndrome (SIRS) if 
the infectious agent overwhelms the initial immune response. Although SIRS is seen in other 
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conditions such as pancreatitis, trauma and burns, it is differentiated in sepsis by the presence of 
an infectious agent (Balk 2014). SIRS/sepsis is characterized by marked increase in 
inflammatory cytokine levels including tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-
1β), and interleukin-6 (IL-6) in the earlier stages and by high mobility group box 1 (HMGB1) 
during the later phase (Schulte, Bernhagen et al. 2013). While sepsis is generally thought to be 
pro-inflammatory in nature, it has been recently proposed that the uncontrolled hyper-
inflammatory state is usually followed or counteracted by compensatory anti-inflammatory 
response syndrome (CARS) that tries to protect the host from excessive inflammatory insult 
(Ward, Casserly et al. 2008). If the infection is not checked, SIRS can overwhelm the CARS 
response which can lead to the development of septic shock and multiple organ dysfunctions. 
Although previous studies have focused on detecting different microorganisms responsible for 
sepsis, the recent approach has centered on identifying the relation between sepsis and the 
immune response. The SIRS response is caused by an excess production of reactive oxygen 
species (ROS) and reactive nitrogen species (RNS) that adversely affect the normal cellular 
processes (Biswal and Remick 2007). While it remains unclear whether mitochondrial 
dysfunction is the initiating cause of the excess ROS formation or whether increased ROS 
amplifies ROS production cycle in the mitochondria (Galley 2011). Given the role that ROS is 
thought to play in sepsis progression, it has been hypothesized that anti-oxidants may be a 
beneficial strategy to treat sepsis. The current treatment regime of sepsis largely resides on the 
use of antibiotics and intravenous fluids which are largely ineffective in the final stages of sepsis 
(Daniels 2011).  
In recent years the study of nanotechnology has given rise to several anti-oxidants that 
exhibit auto-regenerative properties. The cerium oxide nanoparticle (CeO2) is one of those 
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compounds that is currently used as a polishing agent in industry and as a catalyst to improve 
fuel combustion (Dunnick, Pillai et al. 2015). In the biomedical field, CeO2 nanoparticles have 
been shown to treat cancer (Pesic, Podolski-Renic et al. 2015), stroke (Estevez, Pritchard et al. 
2011) and diabetes (Rocca, Moscato et al. 2015). Recent studies have also shown that these 
nanoparticles are capable of preventing cell damage and death induced by ROS because of their 
anti-oxidant properties (Arya, Sethy et al. 2014). Whether nanoceria can be used to treat splenic 
damage seen in sepsis is not well understood. 
Specific Aim 1 
To determine whether CeO2 nanoparticles can attenuate sepsis induced splenic damage. 
Hypothesis 
CeO2 nanoparticles will attenuate sepsis induced structural damage in spleen and also 
attenuate expression of HMGB1 in spleen. 
Specific Aim 2 
To determine whether CeO2 nanoparticles can attenuate polymicrobial insult associated 
increase in microbial load in blood and peritoneal fluid.  
Hypothesis 
CeO2 nanoparticles will attenuate the sepsis associated increase in bacterial number in 
blood and peritoneal fluid. 
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CHAPTER 2  
REVIEW OF LITERATURE 
The current chapter provides a review of literature regarding sepsis as well as the 
potential applications of nanotechnology in the treatment of inflammatory diseases.  The 
following research topics are discussed: 1. Etiology and pathophysiology of sepsis, 2. Splenic 
dysfunction in sepsis, 3. Current research on sepsis and its management, and 4. Nanomedicine 
and applications of CeO2 nanoparticles for the treatment of inflammatory diseases. 
Etiology and Pathophysiology of Sepsis 
Sepsis is a serious pathological condition that is on constant rise and ranks among the top 
ten mortality causing diseases in United States (Mayr, Yende et al. 2013). Each year 
approximately 700,000 cases are registered in the United States and nearly 200,000 cases result 
in death (Burchardi and Schneider 2004). The major causes of sepsis are bacterial infection 
followed by fungi, viruses, and parasites (Tupchong, Koyfman et al. 2015). The process of sepsis 
normally begins with the entry of an infectious agent into the host. When the invading pathogen 
is highly infectious with a very short incubation period, an uncontrolled immune response can 
arise. This response is characterized by the release of several inflammatory cytokines such as 
TNF-α, IL-1β and IL-6 that further drive sepsis progression (Tupchong, Koyfman et al. 2015). 
The resulting “cytokine storm” is known as systemic inflammatory response syndrome (SIRS) 
and is characterized by increase in body temperature greater than 38 °C or less than 36 °C, 
increase in heart rate above 90 beats/minute, increase in respiratory rate above 20 breaths/minute 
along with change in white blood cell count with greater than 12,000/µL or less than 4,000/µL 
(Comstedt, Storgaard et al. 2009). Usually, the inflammatory insult can be successfully brought 
under control with appropriate medical intervention in a timely manner. However, without 
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intervention, SIRS can damage the vascular endothelial barrier resulting in the leakage of plasma 
into the extracellular space (Jacobson and Garcia 2007).  A loss in circulating volume, in turn, 
can result in the development of hypotension and decreased supply of nutrients to the 
metabolically active cells. These sequences of events result in septic shock and can progress to 
multiple organ dysfunctions. Failure of four or more organs usually account for 65% of the 
deaths in hospitalized patients (Grozdanovski, Milenkovic et al. 2012). Thus far, clinical trials to 
improve sepsis survival have been for the most part ineffective. Although not fully understood, it 
is thought that differences in sepsis severity and sepsis classification have complicated clinical 
progress. According to the American College of Chest Physicians/Society of Critical Care 
Medicine consensus, sepsis is defined as the presence of at least two SIRS criteria in the 
presence of an infectious agent while severe sepsis is characterized by sepsis plus marked 
hypotension/hypo perfusion and multiple organ failure (Martin 2012).  
At the cellular level, the immune response starts with the interaction between the 
lipopolysaccharide (LPS) portion of gram negative bacteria and the cluster of differentiation 14 
(CD14) co–receptor (Sagy, Al-Qaqaa et al. 2013). CD14 is a glycosylphosphatidylinositol 
anchored protein that occurs in a receptor form and as a soluble protein in the circulating blood 
stream. The LPS-CD14 complex binds to the toll-like receptor 4 (TLR-4) which undergoes 
oligomerization and initiates downstream intracellular signaling (Van Amersfoort, Van Berkel et 
al. 2003). Activation of TLR-4 receptors results in propagation of signals in one of two 
downstream effector pathways, the myeloid differentiation primary response gene 88 (MYD-88) 
dependent and independent pathways (Van Amersfoort, Van Berkel et al. 2003).  
The MYD-88 is a signaling protein with unknown function and contains a C-terminal 
toll/interleukin receptor (TIR) domain and an N-terminal death domain (Deguine and Barton 
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2014). This signaling adaptor protein recruits inter leukin-1 receptor associated kinase 4 
(IRAK4) and upon activation causes activation of downstream protein tumor necrosis receptor-
associated factors (TRAF) (Deguine and Barton 2014). The TRAF 6, a member of the TRAF 
protein family, then activates transforming growth factor beta-activated kinase (TAK1), a serine-
threonine kinase that further propagates the signal through the nuclear factor kappa B (NF-κB) 
and mitogen activated protein kinase (MAPK) pathways (Akira and Takeda 2004). The NF-κB is 
a transcription factor that is responsible for the synthesis and release of several inflammatory 
mediators. 
The MYD-88 independent pathway requires adaptor molecules TIR-domain-containing 
adapter-inducing interferon-β (TRIF) and thyroid receptor activator molecule (TRAM) for TLR-
3 and TLR-4 signaling (Bagchi, Herrup et al. 2007). TRAF3 recruited by TRIF is involved in the 
activation of downstream interferon regulatory factor 3 (IRF3) which is necessary for NF-κB late 
phase activation (Bagchi, Herrup et al. 2007). IRF3 and NF-κB activation in turn leads to 
production of interferons that are responsible for protecting the host against invading bacteria, 
viruses, and fungi. 
The inflammatory process is involved in the release of chemical mediators such as 
histamines, cytokines, and prostaglandins from macrophages, neutrophils, and lymphocytes. 
These inflammatory mediators act in both an autocrine and paracrine manner on various cell 
types. The activation of immune cells also results in production and release of nitric oxide (NO). 
NO is an anti-microbial agent and at the same time, a potent vasodilator (De Cruz, Kenyon et al. 
2009). NO in conjunction with inflammatory cytokines lead to vasodilation and disruption of 
endothelial barrier that can result in plasma leakage, subsequent hypo perfusion, and multi-organ 
failure (Hauser, Matejovic et al. 2008). 
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Splenic Dysfunction in Sepsis 
The spleen, the body’s largest lymphoid organ, plays an important role in protecting the 
host against pathological agents and also acts as filter for circulating blood (Altamura, 
Caradonna et al. 2001). One of the major functions of spleen is the modulation of the immune 
response and maintenance of peripheral tolerance (Bronte and Pittet 2013). The spleen is also 
required for the activation and differentiation of T and B lymphocytes upon invasion by 
pathogenic microorganisms (Liu 1997). As such, diminished or impaired splenic function in 
patients is associated with high risk of severe sepsis.  
Studies have shown that the removal of the spleen is associated with a 10-20 fold higher 
risk of sepsis and sepsis-induced mortality (Tarantino, Scalera et al. 2013). The depletion of 
functionally matured T-helper cells directly affects the ability to generate immune responses 
against invading pathogens. Previous studies in animal models of sepsis have shown that 
apoptosis of lymphocytes is mediated by both death receptor and mitochondrial pathways 
(Hotchkiss, Swanson et al. 1999). Overexpression of the B cell lymphoma-2 (Bcl-2) anti-
apoptotic protein increased survival in septic animals by preventing mitochondrial damage 
(Hotchkiss, Swanson et al. 1999, Iwata, Stevenson et al. 2003). Similarly, others have reported 
that blockage of the apoptosis antigen 1 (Fas) death receptor is also associated with improved 
survival following a septic insult (Ayala, Chung et al. 1999). More recently, it has been shown 
that levels of HMGB1, a late phase inflammatory cytokine is associated with splenomegaly. In 
addition, the administration of anit-HMGB1 antibodies attenuated splenomegaly (Valdes-Ferrer, 
Rosas-Ballina et al. 2013) suggesting that therapeutic approaches to target HMGB1 could 
attenuate sepsis associated splenic dysfunction and lymphocyte apoptosis. 
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Current Research on Sepsis and its Management 
Understanding the pathogenesis of sepsis is of paramount importance to developing 
optimal therapeutic strategies. Because of the difficulties associated with performing invasive 
studies in humans, most of the initial sepsis research is done in animals. Commonly used sepsis 
animal models include: a) the lipopolysaccharide model (LPS), b) inoculation of live bacteria, c) 
cecal ligation and puncture (CLP), d) colon ascendens stent peritonitis (CASP), and e) 
polymicrobial sepsis (fecal peritonitis/ cecal inoculum) (Buras, Holzmann et al. 2005). Each 
model of sepsis has unique advantages and disadvantages. The LPS model of sepsis is quick in 
onset and more aptly describes the cytokine storm seen in human sepsis (Doi, Leelahavanichkul 
et al. 2009). In comparison, studies that apply live bacteria usually involve only type of bacteria 
(Gram-negative or gram-positive) and do not mimic the polymicrobial nature of human sepsis 
(Doi, Leelahavanichkul et al. 2009). To overcome these deficiencies, researchers have developed 
a fecal peritonitis of sepsis model that is polymicrobial in nature. However, even this animal 
model is not error free, as the sudden onset of microbial colonization typically does not mimic 
the gradual progression of sepsis seen in humans. Nonetheless, the amount of bacterial load can 
be controlled in this model and as such the variability associated is low (Garrido, Figueiredo et 
al. 2004). The CLP model of sepsis is currently considered as the gold standard model of sepsis 
(Dejager, Pinheiro et al. 2011). This model involves ligation of and puncture of cecum through 
which the cecal material extrudes over time into peritoneal space (Nemzek, Hugunin et al. 2008). 
A major disadvantage of this model is the variability in response seen from one animal to other 
due to the differences in the amount of cecal content that extrudes into the peritoneal space 
(Dejager, Pinheiro et al. 2011). As such, the choice of model used is typically based on the 
hypothesis of the study.  
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The initial studies regarding sepsis treatment were, for the most part, based on identifying 
the type of bacteria and treating them with suitable antibiotics. Recent studies suggest that 
antibiotics play an important role in the early stages of sepsis where they tend to prevent their 
multiplication giving the host immune system tries to clear the infection from the circulation 
(Daniels 2011). However, it has also been shown that administration of antibiotics at later phases 
of sepsis is of little benefit as it is the cytokine storm that causes the multi-organ failure and 
septic shock (Ferrer, Martin-Loeches et al. 2014). With increasing antibiotic resistance and delay 
in administration, research regarding sepsis treatment has shifted towards the development of 
anti-oxidants that could scavenge ROS and prevent the cytokine storm associated organ failure 
(Andrades, Morina et al. 2011).  
Oxidative stress occurs when there is an imbalance between production of ROS and the 
total antioxidant capacity of the cell (Galley 2011). Oxidative stress has been shown to initiate 
activation of the redox sensitive transcription factor nuclear factor-kappa-B (NF-κB) in septic 
patients (Macdonald, Galley et al. 2003). It is thought that this transcription factor is responsible 
for the synthesis of the inflammatory mediators which initiate the development of the SIRS 
response (Arnalich, Garcia-Palomero et al. 2000). What causes the ROS that initially activates 
NF-ĸB is currently unknown. While the mitochondria are the major ROS producing organelles of 
the cell, it is unclear whether mitochondrial dysfunction precipitates the oxidative stress or 
conversely, whether oxidative stress contributes to mitochondrial failure and the generation of 
ROS (Galley 2011). Lowes and colleagues, have shown that intravenous administration of potent 
antioxidants such as MitoQ and MitoE that specifically accumulate in mitochondria can attenuate 
LPS-induced increases in IL-6 levels and increase animal survivability (Lowes, Webster et al. 
2013). In another study, Zapelini and co-workers, demonstrated that the administration of NAC 
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several hours after the induction of sepsis by CLP attenuated cytochrome-c release from 
mitochondria along with mitochondrial swelling (Zapelini, Rezin et al. 2008). While these 
studies were targeted at observing the effects of anti-oxidants in sepsis on mitochondria, it 
should be noted that small levels of anti-oxidants were also present in cytoplasm. As such, it is 
difficult to specifically determine the role of mitochondrial dysfunction might play in sepsis 
progression. Nonetheless, other studies using different anti-oxidants including vitamin E (Yao, 
Carlson et al. 2015), vitamin C (Kim, Ha et al. 2015), and melatonin (Kleber, Kubulus et al. 
2014) have also shown survival benefit in animal models of sepsis when given in combination 
with conventional antibiotic and intravenous fluid therapy.  
Nanomedicine and Applications of CeO2 Nanoparticles for the Treatment of Inflammatory 
Diseases 
Nanotechnology is characterized by the study and application of matter at the atomic and 
molecular level (Patil, Mehta et al. 2008). Nanomedicine is one particular area of 
nanotechnology of increasing importance. At outgrowth of this area is the development of 
nanoparticles or nano-devices for the treatment of several different pathologies including cancer 
(Paulmurugan, Bhethanabotla et al. 2015), stroke (Panagiotou and Saha 2015), and diabetes 
(Sharma, Sharma et al. 2015). Nanoparticles are particles between 1 and 100 nm in size. As 
particle size decreases, the surface to volume ratio greatly increases which can lead to increased 
therapeutic efficacy (Jena, Mishra et al. 2013). Of particular interest, researchers are now trying 
to employ the use of nanoparticles in the treatment of pathological diseases that are characterized 
by increased ROS. Elevated levels of ROS are seen in stroke, sepsis, diabetes, and other 
cardiovascular pathologies. Currently, conventional anti-oxidants such as edaravone or N-acetyl 
cysteine are being used to treat stroke and Parkinson’s disease (Lapchak 2010). While effective 
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in action, one of the major drawbacks with this treatment is the need for repetitive administration 
over long periods of time. In contrast nanotechnology has given rise to several nanoparticles that 
act as catalytic ROS scavengers that can function for long periods of time in the body. One such 
compound are the SOD-conjugated poly (D, L-lactic-co-glycolic acid) (PLGA) nanoparticles 
developed by Reddy and coworkers to treat cerebral ischemia reperfusion injury in rats (Reddy 
and Labhasetwar 2009). Similarly platinum nanoparticles have also been shown to possess 
catalase mimetic activity that can be used to scavenge superoxide and even increase life span in 
C. elegans (Kim, Shirasawa et al. 2010). 
Cerium oxide (CeO2) nanoparticles are perhaps the most widely used anti-oxidant 
nanoparticles in the biomedical field. Cerium belongs to the lanthanide series of transition metals 
and it exhibits that capability to cycle between Ce
+3
 and Ce
+4
 depending on the surrounding 
environment (Pulido-Reyes, Rodea-Palomares et al. 2015). This unique property of nanoceria 
allows it to scavenge ROS for an extended period of time. Furthermore, in therapeutic doses 
these nanoparticles have been shown to be largely non-toxic (Hirst, Karakoti et al. 2013). CeO2 
nanoparticles have been shown to inhibit the progression of ovarian cancer (Giri, Karakoti et al. 
2013) and decrease insulin resistance (Rocca, Moscato et al. 2015) in animal models. Kolli and 
coworkers demonstrated that these nanoparticles can also inhibit the development of 
monocrotaline induced right ventricular hypertrophy by scavenging ROS (Kolli, Manne et al. 
2014). Similarly, Oro and coworkers, have shown that CeO2 nanoparticles can attenuate carbon 
tetrachloride-induced liver fibrosis by attenuating the expression of the EPX, NCf1 and NCf2 
proteins that are involved in oxidative stress (Oro, Yudina et al. 2015). In addition, CeO2 
nanoparticles have also been shown to possess anti-bacterial activity (Shah, Shah et al. 2012). A 
study by Babu and coworkers, demonstrated that gold supported CeO2 nanoparticles exhibited a 
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strong inhibitory effect on Bacillus subtilis, Salmonella enteritidis, Escherichia coli, and 
Staphylococcus aureus (Babu, Anandkumar et al. 2014).  In an in vivo model, CeO2 
nanoparticles have been shown to reduce sepsis induced mortality by scavenging reactive oxygen 
species in the liver (Manne, Arvapalli et al. 2015) and kidneys (Selvaraj, Nepal et al. 2015). 
Whether, CeO2 nanoparticles provide protection against sepsis induced splenic damage is not 
known. 
Nanotechnology is a recent scientific discipline that has its branches rooted in several 
fields including medicine. Recently, nanotechnology has given rise to new devices that can 
effectively clear bacteria from the circulation (Kang, Super et al. 2014) along with various 
nanoparticles that are anti-microbial (Ramalingam, Rajaram et al. 2014) and anti-inflammatory 
(Lai, Shieh et al. 2015) in nature. Cerium oxide (CeO2) nanoparticles exhibit potent anti-oxidant 
activity (Caputo, De Nicola et al. 2015) and can exist in both oxidized and reduced states 
(Walkey, Das et al. 2015). This latter ability provides CeO2 nanoparticles with the capacity to 
absorb free radicles. Recent studies have suggested that these particles may be useful for treating 
several pathologies including cancer (Pesic, Podolski-Renic et al. 2015), cardiovascular disease 
(Kolli, Manne et al. 2014), and diabetes (Pourkhalili, Hosseini et al. 2011). Previous work has 
also shown that CeO2 nanoparticles can act as a superoxide dismutase mimetic (Korsvik, Patil et 
al. 2007) and this property has been exploited for the treatment of right ventricular hypertrophy 
(Kolli, Manne et al. 2014), hypoxia (Arya, Sethy et al. 2013), endometriosis (Chaudhury, Babu 
et al. 2013), wound healing (Chigurupati, Mughal et al. 2013) and autoimmune encephalitis 
(Eitan, Hutchison et al. 2015). In addition, other investigation has shown that CeO2 nanoparticles 
can inhibit the growth of pathogenic bacteria such as E. coli and B. subtilis by adsorbing on to 
their membranes (Pelletier, Suresh et al. 2010).  
 
 
13 
Previous work by our laboratory has demonstrated that CeO2 nanoparticles can prevent 
polymicrobial insult-induced mortality, decreased systemic cytokine levels and attenuated liver 
and renal failure (Manne, Arvapalli et al. 2015). The action of CeO2 nanoparticles on a spleen 
following polymicrobial insult is not known. Our findings suggest that a single dose treatment 
with CeO2 nanoparticles can be used to attenuate splenic damage, reduce the levels of the pro-
inflammatory cytokine high mobility box group 1(HMGB1) and that these findings were also 
associated with decreased bacterial load in the circulation.  
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CHAPTER 3 
MATERIALS AND METHODS 
CeO2 Nanoparticle Characterization 
Nanoparticles were purchased from US Research Nanomaterials Inc. (Houston, TX) and 
characterized. Structural characterization of the CeO₂ nanoparticles was performed using a JEOL 
JSM-6320F field emission scanning electron microscope (FESEM).  The particle size of the 
CeO2 nanoparticles was determined by transmission electron microscopy using a JEOL JEM-
2010 transmission electron microscope (TEM) operated at 300 Kev. Energy dispersive X-ray 
spectroscopy was performed to determine the purity of sample. 
Animal Model of Polymicrobial Sepsis and Therapeutic Intervention 
Ten week old male Sprague Dawley rats were purchased from Hill-Top laboratories and 
housed two-per cage at 22 ± 2° C with a 12:12 light-dark cycle. Animals were allowed to 
acclimate to their surroundings for two weeks before any experimentation. Animals were fed 
with standard rodent chow and had access to food and water ad libitum during the entire study. 
All surgical procedures were performed in accordance with the guidelines provided by the 
Marshall University Institutional Animal Care and Use Committee (IACUC) and The 
Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Briefly, 
animals were deeply anesthetized under isoflurane and a small mid ventral incision of 0.5 cm 
was made. Sham controls and CeO2 nanoparticles only groups were injected with 5 ml/kg of 5% 
sterile dextrose solution intraperitoneally. The incision was closed with 3-0 silk sutures as 
described elsewhere. For sepsis and sepsis+CeO2 nanoparticles groups, animals received a cecal 
inoculum of 600 mg/kg BW in 5 ml/kg BW of 5% sterile dextrose solution intraperitoneally. 
Cecal material was collected from the caecum of healthy rats following sacrifice under isoflurane 
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anesthesia. Two hundred microliters of sterile distilled water was injected intravenously via the 
tail vein to animals in the sham control and sepsis groups while the CeO2 and sepsis + CeO2 
groups received CeO2 nanoparticles (0.5 mg/kg) in 200 µl of sterile distilled water as described 
previously (Manne, Arvapalli et al. 2015).  Animals were randomly assigned to one of the four 
groups and were sacrificed at 3 h and 18 h after sepsis induction to study the molecular events 
during early and late phases of sepsis.  
Collection and Preservation of Spleen 
Animals from different groups were sacrificed under anesthesia at 3h and 18h after sepsis 
induction. Peritoneal fluid was collected with a sterile syringe while whole blood was collected 
through cardiac puncture. Spleen was collected and washed with Krebs–Ringer bicarbonate 
buffer (KRB) to remove any blood, blot dried and frozen in liquid nitrogen. Spleens were stored 
at -80°C for further experiments. 
Histology 
Frozen spleens were sectioned (8μm) using Leica CM1950 cryostat onto poly-L-lysine 
coated slides at -18°C and then stored at -80°C. Hematoxylin and eosin staining was performed 
using BBC Biochemical H & E staining kit (Cat No. NC9960321, Fisher Scientific, Pittsburgh, 
PA) on frozen spleen sections to visualize the change in red pulp and white pulp morphology 
with sepsis and CeO2 nanoparticle treatment. Briefly, frozen sections were washed with running 
tap water and stained with Harris hematoxylin for 5 min. Slides were then washed with water for 
1 min and then with acid wash for 45 s. This was followed by washing and incubation with 
blueing solution for 15 s. Slides were washed again, incubated with 70% alcohol for 30 s and 
Eosin for 1 min. After alcohol dehydration and xylene clearing the splenic morphology was 
visualized using an Evos XL microscope (Life technologies, Grand Island, NY). 
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SDS-PAGE and Immunoblotting 
Approximately 50 mg of frozen spleen tissue was measured and pulverized in liquid 
nitrogen. Four hundred and fifty microliters of T-PER (Pierce, Rockford, IL, USA) containing 
1% protease and phosphatase inhibitors (P8340 and P5726, Sigma- Aldrich, St. Louis, MO, 
USA) was added to the sample, the samples homogenized and then centrifuged at 5,000 x g for 
15 min at 4°C to collect the supernatant. The 660 nm assay (Pierce, Rockford, IL, USA) was 
performed to determine the protein content in the supernatant and the samples were normalized 
with T-PER and 4x Laemlli buffer to obtain equal protein concentration across all samples. Forty 
micrograms of protein were loaded in 10% PAGEr Gold Precast gel (Lonza, Rockland, ME) and 
transferred to nitrocellulose membranes as described elsewhere (Selvaraj, Nepal et al. 2015). 
Nitrocellulose membranes were then blocked with 5% milk in Tris-Buffered saline with 0.05% 
Tween-20 (TBST) for 1h at room temperature, washed three times with TBST and probed with 
antibodies specific for Bax, cleaved caspase 3, caspase 3, HMGB1, and GAPDH (Cell Signaling 
Technology, Danvers, MA). Membranes were incubated with primary antibody for 16 h at 4° C 
and washed three times with TBST for 5 min each. After incubation with a secondary anti-rabbit 
antibody (Cell Signaling Technology, Danvers, MA) for 1 h at room temperature, 
immunoreactivity was visualized using Super signal West Pico Chemiluminescent substrate 
(Pierce, Rockford, IL, USA) and quantified using Fluorchem 9900 software (Protein Simple, 
Santa Clara, CA). Protein expression relative to glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used to normalize protein expression. 
Bacterial Cultures 
Whole blood was collected via cardiac puncture and peritoneal lavage fluid was obtained 
using a sterile syringe. Blood and peritoneal lavage samples were serially diluted in sterile saline 
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and plated on sheep’s blood agar/ nutrient agar plates. Plates were incubated overnight at 37° C 
and colony counts were determined 24 hours later. Colony counts were expressed as CFU/ml of 
fluid and then converted to a logarithmic scale for statistical analysis. 
Statistical Analysis 
Results are presented as mean ± standard error of mean. One way analysis of variance 
(ANOVA) was performed to detect significant differences in means. Post hoc comparisons were 
done using a Student Newman Keul’s test for normally distributed samples or a Kruskal-Wallis 
one-way ANOVA by ranks for samples exhibiting a non-normal distribution. A probability value 
of P < 0.05 was considered to be statistically significant. 
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RESULTS 
Nanoceria Characterization 
Field emission scanning electron microscopy demonstrated that the nanoparticles were 
round to spherical in shape (Figure 1A). Transmission electron microscopy demonstrated the 
typical lattice structure of the nanoparticles with an approximate diameter of 10-20 nanometers 
(Figure 1B). 
Cerium Oxide Nanoparticles Attenuate the Splenic Damage Induced by Polymicrobial 
Sepsis 
Compared to that observed in the controls, polymicrobial sepsis did not result in 
extensive splenic damage/necrosis in early stages (3h) of sepsis (Figure 2, A-D). Conversely, in 
the latter stages of sepsis (18h) polymicrobial insult appeared to result in the loss of lymphocyte 
rich white pulp (Figure 2, E, and G). Cerium oxide nanoparticle treatment appeared to attenuate 
the loss of white pulp in at the 18h time point (Figure 2, G and H). 
Cerium Oxide Nanoparticle Treatment Attenuates Sepsis Associated Increases in Splenic 
HMGB1 Expression 
Previous studies have shown sepsis is associated with a massive increase in the splenic 
levels of HMGB1 (Valdes-Ferrer, Rosas-Ballina et al. 2013).  Consistent with this finding, 
HMGB1 expression was increased with sepsis at 3h and 18h after induction (Figure 3A). 
Consistent with our histological findings of improved tissue splenic structure, nanoparticle 
treatment decreased HMGB1 levels at 18h time point (Figure 3A). 
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Apoptosis is not a Major Pathway for Splenic Cell Death in the Polymicrobial Inoculum 
Sepsis Model 
Although recent data has suggested that lymphocyte apoptosis in the spleen is increased 
in the cecal ligation and puncture sepsis model (Hotchkiss, Coopersmith et al. 2005) we did not 
find similar evidence in the CI model. Specifically, sepsis did not appear to increase the levels of 
apoptotic proteins Bax, cleaved caspase 3 and caspase 3 in the spleen (Figure 4A, B, and C). 
Similarly, treatment with CeO2 nanoparticles did not appear to affect splenocyte death.  
Cerium Oxide Nanoparticles Attenuate Bacterial Load in The Blood And Peritoneal Fluid 
of Septic Animals 
The number of CFU in the blood and peritoneal fluid were significantly increased at 18h 
in the septic animals which were decreased with nanoparticle treatment (Figure 5, A-B). 
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Discussion 
Despite considerable improvements in medical technology, millions of people die from 
sepsis each year. With growing antibiotic resistance and the emergence of new pathogens, the 
need to develop new safe and effective drugs is of paramount significance. CeO2 nanoparticles 
are potent anti-oxidants and that they might be beneficial for the treatment of cancer (Giri, 
Karakoti et al. 2013), stroke (Estevez, Pritchard et al. 2011) and other diseases characterized by 
increased systemic ROS levels. Recent studies have shown that cerium oxide nanoparticles are 
effective able to reduce mortality in Sprague Dawley rats subjected to polymicrobial insult 
(Manne, Arvapalli et al. 2015). Conversely, other work has suggested that CeO2 nanoparticles 
may be toxic to cells and that they might cause tissue damage and remodeling (Aalapati, 
Ganapathy et al. 2014). Why different studies may arrive at different results is currently 
unknown, but could be related to differences in nanoparticle size, shape and charge (Das, 
Dowding et al. 2013). In an effort to better understand the relationship between nanoparticle 
morphology and biological activity, we first characterized the particles using electron 
microscopy. Consistent with our previous data (Manne, Arvapalli et al. 2015), nanoparticles 
were spherical in shape with an average size of 10-30nm in diameter (Figure 1). 
Previous studies have shown that there is loss in white pulp (lymphocytes) in spleen with 
sepsis. To confirm whether CeO2 nanoparticles can prevent the loss of white pulp, hematoxylin 
and eosin staining was performed on frozen spleen sections. CeO2 nanoparticle treatment 
attenuated the loss of white pulp which appeared to maintain the structural integrity of spleen 
(Figure 2). Using the mouse CLP sepsis model, Hotchkiss and colleagues, demonstrated that 
apoptosis is the major mechanism of lymphocyte cell death in spleen with sepsis (Hotchkiss, 
Tinsley et al. 1999). In particular, they found that sepsis was associated with a significant amount 
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of CD4+ T cell death. To investigate whether a similar phenomenon occurs in our animal model, 
immunoblotting was performed to evaluate the expression of apoptotic regulators Bax, cleaved 
caspase 3 and caspase 3. Interestingly, we failed to find any sepsis-associated increase in cell 
death. Why our results might differ from those found by Hotchkiss and co-workers is not entirely 
clear, but might be due to difference in the sepsis model used. Unlike the CLP model which 
exhibits a slow septic progression, the cecal inoculum model is rapid in onset. As such, the cell 
death seen in the cecal inoculum model may occur via necrosis rather than apoptosis. Similarly, 
because the T cells make up only a small percentage of the total spleen cell number, it is possible 
the presence of T cell apoptosis could be obscured or diluted by looking at apoptotic events using 
whole organ lysates. Repeating these studies after the isolation of specific cell types prior to 
investigating apoptotic signaling may be beneficial in furthering our understanding of the roll 
that cellular apoptosis may play in the spleen of animals subjected to the cecal inoculum model 
of sepsis.  
Recent studies have shown that HMGB1, a nuclear protein, is released during late phase 
of sepsis into circulation and that it is highly correlated with organ failure and sepsis progression 
(Huang, Tang et al. 2010, Wang, Ward et al. 2014). Several clinical trials have also demonstrated 
high levels of HMGB1 in blood of septic patients (Angus, Yang et al. 2007) and that 
administration of anti-HMGB1 antibody has been shown to be organ protective (Qin, Wang et al. 
2006).  In relation to this, Jared and coworkers, have shown that the removal of the spleen can be 
protective in some instances of sepsis as it appears to reduce circulating HMGB1 levels (Huston, 
Wang et al. 2008). Here, for the first time, we show that intervention with CeO2 nanoparticles 
can attenuate the levels of HMGB1 in septic spleen (Figure 3). Whether this decrease in HMGB1 
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alone can explain the increased animal survival seen in CeO2 treated animals is currently unclear 
and will require further investigation.  
In an effort to extend our findings on the therapeutic efficacy of CeO2 nanoparticles, we 
next evaluated the bacterial load in blood and peritoneal fluid of septic animals. Spleen plays an 
important role in immune mediated bacterial clearance and that loss in splenic function would 
attenuate the pathogen clearance. Here we found that treatment with the CeO2 nanoparticles was 
associated with diminished bacterial load in both the blood and peritoneal fluid (Figure 4). 
Whether this attenuation is due to a direct effect of CeO2 nanoparticles on splenic lymphocyte 
population, the liver Kupffer cells or circulating monocytes is not known and is a potential 
subject for future investigation.  
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FIGURES 
Figure 1  Characterization of CeO2 nanoparticles.  
A) Field emission scanning electron microscopy (FESEM) B) Transmission electron microscopy 
(TEM) C) Energy dispersive X-ray spectroscopy (EDS). 
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Figure 2 CeO2 nanoparticles attenuate severe sepsis induced inflammatory damage in 
spleen. 
A-D) Hematoxylin and eosin (H&E) staining of 3h time point spleen sections imaged at 200× 
magnification - Control, CeO2, Sepsis, and Sepsis + CeO2. E-H) Hematoxylin and eosin (H&E) 
staining of 18h time point spleen sections imaged at 200× magnification - Control, CeO2, Sepsis, 
and Sepsis + CeO2  (n=3/group). Note: loss of white pulp in sepsis 18h (arrow). 
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Figure 3 CeO2 nanoparticles attenuate severe sepsis induced increase in expression of pro-
inflammatory cytokine HMGB1. 
 *P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared 
to sepsis group. (n=6/group). 
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Figure 4  Cecal inoculum method of polymicrobial sepsis does not induce caspase 3 
mediated apoptosis in spleen. 
 A) Total protein levels of Bax at 3h and 18h in Control, CeO2, Sepsis, and Sepsis + CeO2 
groups. B) Levels of cleaved caspase 3 at 3h and 18h in Control, CeO2, Sepsis, and Sepsis + 
CeO2 groups. C) Total levels of caspase 3 at 3h and 18h in Control, CeO2, Sepsis, and Sepsis + 
CeO2 groups. (n=6/group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
Figure 5 CeO2 nanoparticles attenuate bacterial load in blood and peritoneal fluid of septic 
animals.  
A) Bacterial load in blood  
B) Bacterial load in peritoneal fluid  
*P<0.05 compared to control group, $ P<0.05 compared to CeO2 group and # P<0.05 compared 
to sepsis group. (n=6/group).
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CHAPTER 4 
CONCLUSIONS 
Sepsis is the leading cause of death in non-coronary intensive care unit in United States 
(Mayr, Yende et al. 2014). Current treatment regimens are largely supportive in nature and fail to 
address the uncontrolled immune response in severe sepsis. CeO2 nanoparticles exhibit potent 
anti-inflammatory activity and that they may have biomedical use for the treatment of stroke 
(Estevez, Pritchard et al. 2011), cancer (Gao, Chen et al. 2014), hepatic steatosis (Oro, Yudina et 
al. 2015) and diabetes (Hosseini, Baeeri et al. 2013).  These particles can also be used to treat 
severe sepsis in Sprague Dawley rats that are subjected to either a LPS (Selvaraj, Nepal et al. 
2015)or a polymicrobial sepsis insult (Manne, Arvapalli et al. 2015). Here we investigated 
whether CeO2 nanoparticles can effect/attenuate splenic damage in Sprague Dawley rats 
subjected to polymicrobial insult. Our data suggest the following:  
1. Histological investigation demonstrated that CeO2 nanoparticle treatment is associated 
with an attenuation of sepsis induced splenic damage. Specifically, we found that 
treatment with CeO2 nanoparticles decreased the loss of white pulp when compared to 
septic animals, 
2. CeO2 nanoparticle treatment functioned to decrease sepsis associated increases in splenic 
HMGB1 expression in the hypo dynamic phase of sepsis. 
3. CeO2 nanoparticle treatment attenuated the bacterial load in the blood and the peritoneal 
fluid of septic animals. 
4. Neither sepsis nor CeO2 nanoparticle treatment affected the protein expression of 
apoptotic regulators in the spleen. 
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Future Directions 
The current study investigated whether CeO2 nanoparticles can attenuate splenic damage 
in the polymicrobial model of sepsis. While the preliminary results indicate that CeO2 
nanoparticle treatment confers some degree of splenic protection, the exact mechanism of action 
is currently unclear. Previous studies have shown that CeO2 nanoparticles accumulate in the 
spleen (Selvaraj, Nepal et al. 2015) and in the liver Kupffer cells (Tseng, Lu et al. 2012) when 
administered intravenously. Whether CeO2 nanoparticles are taken by lymphocyte population or 
the splenic cords after intravenous injection is not known. Determining the site of CeO2 
localization by the isolation of the different splenic cell types and quantification of ceria levels 
by induction coupled plasma mass spectroscopy (ICP-MS) is likely to be invaluable in helping to 
establish where the CeO2 nanoparticles might exert their beneficial effects. Previous studies by 
Hotchkiss and colleagues, demonstrated that sepsis is associated with increased apoptosis of 
splenic CD4
+
, CD8
+
 T cells and CD 19 positive B cells (Hotchkiss, Tinsley et al. 1999). 
Additional experiments using immunohistochemistry to examine the effects of sepsis and the 
nanoparticle treatment on the number of these different cell types is needed to further confirm 
that CeO2 nanoparticles act by modulation of lymphocyte function. 
The sepsis model used in the current study involves administration of a single bolus of 
known quantity of cecal material into peritoneal cavity. Although polymicrobial in nature, it 
more closely models the onset of septic symptoms seen in the LPS model rather than that 
observed in human patients. As such, future experiments using the CLP model which better 
mimics the progression of sepsis seen in humans are likely need to better establish the potential 
efficacy of this nanoparticle based treatment. Similarly, in the current study CeO2 nanoparticles 
were administered at the same time as sepsis induction. It is not known whether CeO2 
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nanoparticles can provide the same degree of therapeutic efficacy when administered during later 
phases of sepsis that is characterized the presence of severe hypotension and uncontrolled 
cytokine storm. Further experiments to test this hypothesis would be very beneficial in 
determining the clinical potential of our approach.  
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